Abrocitinib, an inhibitor of JAK1 that is part of the signaling complex downstream of a number of cytokine receptors including IL-4, IL-13, IL-9, and TSLP, is also in a phase I trial for the treatment of food allergy (NCT05069831). This evidence concerns the gene TSLP and food allergy.